Actuate Therapeutics Inc
ACTUAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Apr 22, 2025 | Craig-Hallum | $21.00(+146%) | $8.52 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 18, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 18, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 22, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Nov 19, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 23, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 18, 2025 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.18| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.20 | $-0.20 | — | — |
| May 14, 2026 | $-0.24 | $-0.23 | — | — |
| Mar 26, 2026 | $-0.18 | $-0.24 | — | — |
| Nov 13, 2025 | $-0.25 | $-0.27 | — | — |
| Aug 14, 2025 | $-0.30 | $-0.19 | — | — |
| May 15, 2025 | $-0.32 | $-0.30 | — | — |
| Mar 13, 2025 | $-0.33 | $-0.29 | — | — |
| Nov 13, 2024 | $-0.55 | $-0.55 | — | — |
News
- Oral tablet formulation of elraglusib as a monotherapy significantly inhibited tumor growth and enhanced antitumor immune activity in an aggressive, poorly immunogenic melanoma model - Phase 1/2 clinical trial evaluating Elraglusib Oral Tablet to be initiated in Q1 2027 CHICAGO and FORT WORTH, Texas, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies …
Oral tablet form expected to allow Company to optimize patient plasma exposure levels with convenient daily dosing of drug
CHICAGO and FORT WORTH, Texas, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced the pricing of an underwritten public offering of 30,985,900 shares of its common stock and warrants to purchase up to an aggregate of 15,492,950 shares of its common stock. The public offering price for each set of two shares of comm…
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced that it will present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026, in New York City. In addition, the management team will be available for one-on-one mee…
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing novel therapies for high-impact, difficult-to-treat cancers, today announced new preclinical data evaluating elraglusib in combination with zoldonrasib (RMC-9805), an investigational RAS(ON) G12D-selective inhibitor, and daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, in pancreatic…
Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.